Form 483

Lotus Pharmaceutical Co., Ltd. Nantou Plant Form 483, 2024-04-12

FDA issued a Form 483 to Lotus Pharmaceutical Co., Ltd. Nantou Plant on 2024-04-12 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

Lotus Pharmaceutical Co., Ltd. Nantou Plant · Nantou County, Taiwan · Issued April 12, 2024

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

12 Apr 2024
21 CFR 211.192

Investigations of discrepancies, failures

Cited by James R Birkenstamm

12 Apr 2024
21 CFR 211.22(a)

Authority lacking to review records, investigate errors

Cited by James R Birkenstamm

12 Apr 2024
21 CFR 211.63

Equipment Design, Size and Location

Cited by James R Birkenstamm

12 Apr 2024
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by James R Birkenstamm

12 Apr 2024
21 CFR 211.68(b)

Computer control of master formula records

Cited by James R Birkenstamm

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 5 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere